“…These results obtained from animal studies are consistent with clinical data showing a reduced selection of high effort alternatives in depressed people tested on tasks of effort-based choice (Treadway et al, 2012;Chong et al, 2016). Administration of the vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine (TBZ), which blocks the monoamine storage and leads to a striatal DA depletion at low doses in primates (Pettibone et al, 1984), rats (Nunes et al, 2013;Podurgiel et al, 2015Podurgiel et al, , 2016Yohn et al, 2015b), and mice (López-Cruz et al, 2018;Carratalá-Ros et al, 2020) has been used to induce effort-related motivational impairments in rodents (Nunes et al, 2014;Yohn et al, 2015bYohn et al, , 2016bCorrea et al, 2018;López-Cruz et al, 2018;Rotolo et al, 2019;Carratalá-Ros et al, 2020). This drug is used in the treatment of Huntington's disease and has been reported to produce depressive symptoms including fatigue in people (Frank, 2009;Guay, 2010).…”